The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial
Dopaminergic dysfunction is implicated in the pathophysiology of treatment-resistant depression. Although the efficacy of adjunctive pramipexole treatment has been demonstrated in treatment-resistant bipolar depression, such data are scarce for major depressive disorder (MDD). We recruited 17 patien...
Saved in:
Main Authors: | Hiroaki Hori, Hiroshi Kunugi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1100/2012/372474 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dopamine Agonists and Pathologic Behaviors
by: Brendan J. Kelley, et al.
Published: (2012-01-01) -
Biological mechanisms of dopamine D2-like receptor agonist therapy in diabetes
by: Zachary Freyberg, et al.
Published: (2025-01-01) -
Dopamine agonists for restless legs syndrome
by: Pran Phakdeekitcharoen, et al.
Published: (2025-02-01) -
Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease
by: Wolfram Eisenreich, et al.
Published: (2010-01-01) -
Hydrogen-oxygen mixture inhalation as an adjunctive treatment to home-based exercise in older patients with knee osteoarthritis: an open-label, blinded-endpoint, randomized controlled trial
by: Chenhui Wang, et al.
Published: (2025-01-01)